Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
13 patients achieved negative measurable residual disease after InO.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The prognosis for patients with R/R B-ALL, particularly those who do not respond to prior immunotherapies, is very poor. InO serves as an effective and safe bridging therapy prior to HSCT.
Among patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), those who failed to respond to CD19-directed immunotherapies, there are limited options available pre-HSCT.
APA
Hu GH, Zuo YX, et al. (2026). Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia.. Leukemia & lymphoma, 67(4), 846-852. https://doi.org/10.1080/10428194.2025.2611117
MLA
Hu GH, et al.. "Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia.." Leukemia & lymphoma, vol. 67, no. 4, 2026, pp. 846-852.
PMID
41498528 ↗
Abstract 한글 요약
Among patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), those who failed to respond to CD19-directed immunotherapies, there are limited options available pre-HSCT. This study aimed to evaluate the efficacy and safety of Inotuzumab ozogamicin (InO) as the definitive treatment pre-HSCT in patients with R/R B-cell B-ALL. Sixteen patients were enrolled, ten of whom failed treatment with prior CD19-directed immunotherapies, and two of whom relapsed after first HSCT. All patients achieved morphologic complete remission; 13 patients achieved negative measurable residual disease after InO. After bridging to HSCT, the 1-year probabilities of leukemia-free survival and overall survival were 66.5% and 80.8%. One patient developed sinusoidal obstruction syndrome post-HSCT. The prognosis for patients with R/R B-ALL, particularly those who do not respond to prior immunotherapies, is very poor. InO serves as an effective and safe bridging therapy prior to HSCT.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Inotuzumab Ozogamicin
- Hematopoietic Stem Cell Transplantation
- Male
- Female
- Child
- Adolescent
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Preschool
- Transplantation
- Homologous
- Treatment Outcome
- Antineoplastic Agents
- Immunological
- Drug Resistance
- Neoplasm
- Antibodies
- Monoclonal
- Humanized
- Prognosis
- Neoplasm Recurrence
- Local
- Recurrence
- Infant
… 외 5개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.